A phase III LIBRETTO-431 multicenter study has evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not ...

Eli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter of this year, which would extend its lead over a rival drug from Blueprint Medicine.